# MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

> **NCT01299376** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 286 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** L50/H12.5/A5
- **DRUG:** L50/H12.5
- **DRUG:** Placebo to L50/H12.5/A5
- **DRUG:** Placebo to L50/H12.5

## Key facts

- **NCT ID:** NCT01299376
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-24
- **Primary completion:** 2011-11-16
- **Final completion:** 2012-09-20
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299376, "MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01299376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*